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Abstract
Laboratory diagnosis and clinical management of inpatients with diarrhoea is complex and time consuming. Tests are often requested
sequentially and undertaken in different laboratories. This causes prolonged unnecessary presumptive isolation of patients, becausemost cases
are non-infectious. Amolecularmultiplex test (LuminexGastrointestinal Pathogen Panel (GPP))was comparedwith conventional testing over
8 months to determine diagnostic accuracy, turnaround times, laboratory costs, use of isolation facilities and user acceptability. A total of 262
(12%) patients had a pathogen detected by conventional methods compared with 483 (22.1%) by GPP. Most additional cases were detected in
patients developing symptoms in the ﬁrst 4 days of admission. Additional cases were detected because of presumed improved diagnostic
sensitivity but also because clinicians had not requested the correct pathogen. Turnaround time (41.8 h) was faster than bacterial culture
(66.5 h) and parasite investigation (66.5 h) but slower than conventional testing forClostridium difﬁcile (17.3 h) and viruses (27 h). The test could
allow simpliﬁed requesting by clinicians and a consolidated laboratory workﬂow, reducing the overall number of specimens received by the
laboratory. A total of 154 isolation days were saved at an estimated cost of £30 800. Consumables and labour were estimated at £150 641
compared with £63 431 for conventional testing. Multiplex molecular testing using a panel of targets allowed enhanced detection and a
consolidated laboratory workﬂow. This is likely to be of greater beneﬁt to cases that present within the ﬁrst 4 days of hospital admission.
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Abstract
Peptide nucleic acid ﬂuorescence in situ hybridization (PNA FISH) is a molecular diagnostic tool for the rapid detection of pathogens directly
from liquid media. The aim of this study was to prospectively evaluate PNA FISH assays in comparison with culture-based matrix-assisted
laser desorption/ionization-time of ﬂight mass spectrometry (MALDI-TOF MS) identiﬁcation, as a reference method, for both blood and
cerebrospinal ﬂuid (CSF) cultures, during a 1-year investigation. On the basis of the Gram stain microscopy results, four different PNA FISH
commercially available assays were used (‘Staphylococcus aureus/CNS’, ‘Enterococcus faecalis/OE’, ‘GNR Trafﬁc Light’ and ‘Yeasts Trafﬁc Light’
PNA FISH assays, AdvanDx). The four PNA FISH assays were applied to 956 positive blood cultures (921 for bacteria and 35 for yeasts) and
11 CSF cultures. Among the 921 blood samples positive for bacteria, PNA FISH gave concordant results with MALDI-TOF MS in 908/921
(98.64%) samples, showing an agreement of 99.4% in the case of monomicrobial infections. As regards yeasts, the PNA FISH assay showed a
100% agreement with the result obtained by MALDI-TOF MS. When PNA FISH assays were tested on the 11 CSF cultures, the results
agreed with the reference method in all cases (100%). PNA FISH assays provided species identiﬁcation at least one work-day before the
MALDI-TOF MS culture-based identiﬁcation. PNA FISH assays showed an excellent efﬁcacy in the prompt identiﬁcation of main pathogens,
yielding a signiﬁcant reduction in reporting time and leading to more appropriate patient management and therapy in cases of sepsis and
severe infections.
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